Journal article
Clinical application of genetically modified T cells in cancer therapy
MH Kershaw, JA Westwood, CY Slaney, PK Darcy
Clinical and Translational Immunology | Published : 2014
DOI: 10.1038/cti.2014.7
Abstract
Immunotherapies are emerging as highly promising approaches for the treatment of cancer. In these approaches, a variety of materials are used to boost immunity against malignant cells. A key component of many of these approaches is functional tumor-specific T cells, but the existence and activity of sufficient T cells in the immune repertoire is not always the case. Recent methods of generating tumor-specific T cells include the genetic modification of patient lymphocytes with receptors to endow them with tumor specificity. These T cells are then expanded in vitro followed by infusion of the patient in adoptive cell transfer protocols. Genes used to modify T cells include those encoding T-ce..
View full abstractRelated Projects (2)
Grants
Awarded by National Science Foundation
Funding Acknowledgements
MHK, PKD and JAW were funded by National Health & Medical Research Council of Australia (NHMRC) Project Grant 1006188. MHK and PKD are supported by Senior Research Fellowships from NHMRC and Grant No. 1066554 from the Cancer Council of Victoria. CYS is supported by a Postdoctoral Fellowship from the National Breast Cancer Foundation of Australia.